Change in Digital Cognitive Test Performance between Solanezumab and Placebo Groups in Preclinical Alzheimer's Disease: Secondary Analyses from the A4 Study
The Journal of Prevention of Alzheimer's Disease · 2024
DOI: 10.14283/jpad.2024.137 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Prevention of Alzheimer's Disease, 2024. Verfasst von K V Papp und 6 weiteren Autor:innen. Beteiligte Einrichtung: Kathryn V. Papp, 60 Fenwood Road; Boston, MA 02115, Telephone: 617-643-5322; Fax: 857-5461, Email Address: kpapp@bwh.harvard.edu. Hauptthemen laut MEDLINE: Alzheimer Disease, Antibodies, Monoclonal, Humanized, Neuropsychological Tests. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
BACKGROUND: Primary results from the Anti-Amyloid in Asymptomatic Alzheimer's disease Study (A4) suggested no benefit of solanezumab on its primary cognitive outcome, a composite of paper and pencil tests (the Preclinical Alzheimer's Cognitive Composite; PACC). OBJECTIVE: To determine whether change in cognitive performance, assessed using the Computerized Cognitive Composite (C3) summary score and C3 individual tests, differed between treatment groups over 240 weeks, differed based on baseline Aβ burden, and tracked with PACC decline. DESIGN: Longitudinal analysis of cognitive change over 240 weeks on the C3 Summary Score and C3 individual tests between participants randomly assigned to solanezumab at a dose of up to 1600 mg intravenously every 4 weeks versus placebo. SETTING: The A4 study took place at 67 sites in Australia, Canada, Japan and the United States. PARTICIPANTS: Cognitively unimpaired older adults (n=1117, Mean Age=71.9, 60.7% female) with elevated brain amyloid levels on 18F-florbetapir positron-emission tomography (PET) at baseline (n=549 in the solanezumab group; n=568 in the placebo group). MEASUREMENTS: Participants completed the C3 battery and PACC every 6 months. The C3 Summary Score combines the Cogstate Brief Battery (CBB)-One Card Learning, the Behavioral Pattern Separation (BPS) Test- Object- Lure Discrimination Index, and the Face Name Associative Memory Exam (FNAME)- Face-Name Matching. RESULTS: Change on the C3 Summary Score was moderately correlated with change on the PACC (Spearman's corr=0.53, 95% CI: 0.49 to 0.57; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kathryn V. Papp, 60 Fenwood Road; Boston, MA 02115, Telephone: 617-643-5322; Fax: 857-5461, Email Address: kpapp@bwh.harvard.edu.
Förderung
- NIA NIH HHS
Zitieren
APA
Papp, K. V., Maruff, P., Rentz, D. M., Donohue, M. C., Liu, A., Aisen, P. S., & Sperling, R. A. (2024). Change in Digital Cognitive Test Performance between Solanezumab and Placebo Groups in Preclinical Alzheimer's Disease: Secondary Analyses from the A4 Study. The Journal of Prevention of Alzheimer's Disease. https://doi.org/10.14283/jpad.2024.137
Vancouver
Papp KV, Maruff P, Rentz DM, Donohue MC, Liu A, Aisen PS, et al. Change in Digital Cognitive Test Performance between Solanezumab and Placebo Groups in Preclinical Alzheimer's Disease: Secondary Analyses from the A4 Study. The Journal of Prevention of Alzheimer's Disease. 2024. doi:10.14283/jpad.2024.137
BibTeX
@article{Papp2024,
author = {Papp, K V and Maruff, P and Rentz, D M and Donohue, M C and Liu, A and Aisen, P S and Sperling, R A},
title = {Change in Digital Cognitive Test Performance between Solanezumab and Placebo Groups in Preclinical Alzheimer's Disease: Secondary Analyses from the A4 Study},
journal = {The Journal of Prevention of Alzheimer's Disease},
year = {2024},
doi = {10.14283/jpad.2024.137}
}
EUVIMED